Technologies for detection of circulating tumor cells: facts and vision

TY - JOUR

T1 - Technologies for detection of circulating tumor cells: facts and vision

AU - Alix-Panabières, Catherine

AU - Pantel, Klaus

N1 - Abkürzung des Journals fehlt (ist gelistet), alles andere ok

PY - 2014/1/7

Y1 - 2014/1/7

N2 - Hematogeneous tumor cell dissemination is a key step in cancer progression. The detection of CTCs in the peripheral blood of patients with solid epithelial tumors (e.g., breast, prostate, lung and colon cancer) holds great promise, and many exciting technologies have been developed over the past years. However, the detection and molecular characterization of circulating tumor cells (CTCs) remain technically challenging. The identification and characterization of CTCs require extremely sensitive and specific analytical methods, which are usually a combination of complex enrichment and detection procedures. CTCs occur at very low concentrations of one tumor cell in the background of millions of normal blood cells and the epithelial-mesenchymal plasticity of CTCs can hamper their detection by the epithelial markers used in current CTC assays. In the present review, we summarize current methods for the enrichment and detection of CTCs and discuss the key challenges and perspectives of CTC analyses within the context of improved clinical management of cancer patients.

AB - Hematogeneous tumor cell dissemination is a key step in cancer progression. The detection of CTCs in the peripheral blood of patients with solid epithelial tumors (e.g., breast, prostate, lung and colon cancer) holds great promise, and many exciting technologies have been developed over the past years. However, the detection and molecular characterization of circulating tumor cells (CTCs) remain technically challenging. The identification and characterization of CTCs require extremely sensitive and specific analytical methods, which are usually a combination of complex enrichment and detection procedures. CTCs occur at very low concentrations of one tumor cell in the background of millions of normal blood cells and the epithelial-mesenchymal plasticity of CTCs can hamper their detection by the epithelial markers used in current CTC assays. In the present review, we summarize current methods for the enrichment and detection of CTCs and discuss the key challenges and perspectives of CTC analyses within the context of improved clinical management of cancer patients.

KW - Antigens, CD45

KW - Antigens, Neoplasm

KW - Cell Adhesion Molecules

KW - Cell Separation

KW - Humans

KW - Immunoassay

KW - Neoplastic Cells, Circulating

KW - Tumor Markers, Biological

U2 - 10.1039/c3lc50644d

DO - 10.1039/c3lc50644d

M3 - SCORING: Journal article

C2 - 24145967

VL - 14

SP - 57

EP - 62

JO - LAB CHIP

JF - LAB CHIP

SN - 1473-0197

IS - 1

ER -